Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹4 Cr.
Stock P/E
426.1
P/B
8.5
Current Price
₹99.2
Book Value
₹ 11.7
Face Value
10
52W High
₹236.1
52W Low
₹ 81.5
Dividend Yield
0%

Transpact Enterprise Overview

Business

Transpact Enterprises Ltd. is primarily engaged in the trading and distribution of medical equipment, devices, and accessories. The company sources these products from manufacturers (both domestic and international) and supplies them to various healthcare providers, including hospitals, clinics, diagnostic centers, and individual practitioners. Its core business model revolves around acting as an intermediary in the medical supply chain, providing access to a range of essential healthcare products. The company generates revenue through the sale of these medical products, capitalizing on the margin between procurement and selling prices.

Revenue Mix

Transpact Enterprises Ltd. operates predominantly in a single business segment: the trading and distribution of medical equipment and supplies. Given its listing on the SME platform, detailed segmental revenue breakdowns beyond this core activity are typically not publicly available. Revenue is primarily derived from product sales across its diverse medical equipment portfolio.

Industry

The Indian medical equipment and supplies industry is characterized by robust growth, driven by increasing healthcare expenditure, a rising burden of chronic diseases, and improving healthcare infrastructure. However, it is also highly fragmented and competitive, with a mix of multinational corporations (MNCs), large domestic manufacturers, and numerous smaller distributors. Transpact Enterprises Ltd. operates as a distributor within this ecosystem, likely positioning itself by focusing on specific geographies, product categories, or by offering competitive pricing and reliable supply chains to its customer base. It is a relatively smaller player compared to large integrated medical device manufacturers or established national distributors.

MOAT

Transpact Enterprises Ltd.'s competitive advantages are likely derived from its established distribution network, strong relationships with healthcare providers in its operational areas, and its ability to efficiently source and supply a diverse range of medical products. However, as a pure-play distributor of third-party products, it faces challenges in building a deep moat. Barriers to entry for distribution are generally lower than for manufacturing. Its ability to maintain competitive pricing, reliable service, and strong customer loyalty would be key to sustaining any advantage, rather than proprietary technology, strong brand equity in products, or high switching costs inherent in its business model.

Growth Drivers

Increasing Healthcare Spending: India's growing economy and rising disposable incomes are leading to higher public and private healthcare expenditure.

Expansion of Healthcare Infrastructure: Development of new hospitals, clinics, and diagnostic centers across India fuels demand for medical equipment and supplies.

Aging Population & Disease Burden: An increasing elderly population and the rising prevalence of chronic and lifestyle diseases drive the need for continuous medical care and related devices.

Technological Advancements: Introduction of new and improved medical devices periodically creates new market opportunities.

Government Initiatives: Policies aimed at improving healthcare access and affordability in India can indirectly boost demand for medical supplies.

Risks

Intense Competition: The medical equipment distribution market is highly competitive, with pricing pressures from numerous domestic and international players.

Supply Chain Dependencies: Reliance on third-party manufacturers for products exposes the company to risks of supply disruptions, quality issues, and changes in manufacturer terms.

Regulatory Changes: Changes in medical device regulations, import duties, or pricing policies by the Indian government could impact profitability.

Technological Obsolescence: Rapid advancements in medical technology mean that inventory can quickly become outdated, leading to potential write-downs.

Working Capital Management: As a trading company, effective management of inventory and receivables is crucial, and inefficient practices could strain liquidity.

Economic Downturns: A slowdown in economic growth could lead to reduced healthcare spending by both public and private entities.

Management & Ownership

Transpact Enterprises Ltd. is typically promoted by individuals who have a significant shareholding in the company, common for companies listed on the SME platform. The promoters (e.g., Mr. Ajay Kumar Mittal) and their families generally hold a substantial equity stake, demonstrating a vested interest in the company's long-term performance. Management quality would be assessed based on their experience in the medical distribution sector, corporate governance practices, and financial performance over time.

Outlook

Transpact Enterprises Ltd. operates in a fundamentally growing sector, driven by India's expanding healthcare needs and infrastructure development. This provides a positive demand backdrop for its medical equipment distribution business. However, the company faces significant challenges typical of the distribution industry, including intense competition, potential pricing pressures, and reliance on external manufacturers for product supply. Its ability to secure exclusive distribution rights for high-demand products, build strong customer loyalty through efficient service, and effectively manage its supply chain and working capital will be critical for sustained profitability and market share growth. While market tailwinds exist, execution excellence in a highly competitive and fragmented landscape remains paramount.

Transpact Enterprise Share Price

Live · BSE · Inception: 2013
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Transpact Enterprise Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Transpact Enterprise Profit & Loss

#(Fig in Cr.) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 0 0 0 0 0 0 0 0 0
Other Income 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 0 0 0 0 0 0
Total Expenditure 0 0 0 0 0 0 0 0 0
Operating Profit -0 -0 -0 -0 -0 -0 -0 -0 0
Interest 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0
Profit Before Tax -0 -0 -0 -0 -0 -0 -0 -0 0
Provision for Tax 0 0 0 0 0 0 -0 -0 -0
Profit After Tax -0 -0 -0 -0 -0 -0 -0 -0 0
Adjustments 0 0 0 0 0 0 0 0 0
Profit After Adjustments -0 -0 -0 -0 -0 -0 -0 -0 0
Adjusted Earnings Per Share -1.6 -3.2 -10.6 -11.2 -1.7 -5.7 -1.7 -2.4 0.2

Transpact Enterprise Balance Sheet

#(Fig in Cr.) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 0 0 0 1 1 1 1 0 0
Minority's Interest 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0 0 0 0 0
Total Current Liabilities 0 0 0 0 1 0 0 0 0
Total Liabilities 0 0 1 1 1 1 1 1 1
Fixed Assets 0 0 0 0 0 0 0 0 0
Other Non-Current Assets 0 0 0 1 1 1 1 0 0
Total Current Assets 0 0 0 0 0 0 0 0 1
Total Assets 0 0 1 1 1 1 1 1 1

Transpact Enterprise Cash Flow

#(Fig in Cr.) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0 0 0 0 0
Cash Flow from Operating Activities -0 -0 0 -1 0 -1 0 0 -0
Cash Flow from Investing Activities -0 -0 -0 0 0 0 0 0 0
Cash Flow from Financing Activities 0 0 0 1 0 -0 -0 0 0
Net Cash Inflow / Outflow 0 0 -0 0 0 -1 -0 0 -0
Closing Cash & Cash Equivalent 0 0 0 0 0 -1 0 0 0

Transpact Enterprise Ratios

# Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) -1.6 -3.24 0 -11.21 -1.66 -5.71 -1.7 -2.35 0.23
CEPS(Rs) -1.6 -3.24 -9.76 -10.24 -0.7 -4.75 -0.74 -1.39 1.19
DPS(Rs) 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 5.81 2.57 0 22.87 21.21 15.5 13.79 11.44 11.68
Core EBITDA Margin(%) 0 0 -202.91 0 -195.71 -138.53 -7.84 0 51.15
EBIT Margin(%) 0 0 -220.26 0 -236.08 -146.33 -17.57 0 6.06
Pre Tax Margin(%) 0 0 -220.32 0 -236.24 -146.33 -17.59 0 5.09
PAT Margin (%) 0 0 -229.52 0 -256.7 -147.27 -17.23 0 10.91
Cash Profit Margin (%) 0 0 -212.17 0 -107.98 -122.47 -7.5 0 56
ROA(%) -19.19 -25.93 -60.34 -47.48 -4.78 -17.8 -6.14 -10.69 1.33
ROE(%) -27.59 -77.28 -804.02 -97.83 -7.53 -31.12 -11.64 -18.63 2.01
ROCE(%) -19.45 -27.62 -66.2 -53.57 -5.23 -21.88 -7.88 -14.52 0.95
Receivable days 0 0 73 0 5.48 0 0 0 218.34
Inventory Days 0 0 252.69 0 2658.11 236.72 11.93 0 55.3
Payable days 0 0 183.41 0 0 124.89 158.37 0 0
PER(x) 0 0 0 0 0 0 0 0 833.69
Price/Book(x) 0 0 0 5.9 7.64 0 6.89 34.45 16.62
Dividend Yield(%) 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0 0 3.6 0 260.25 4.4 10.3 0 92.06
EV/Core EBITDA(x) -2.26 -3.7 -1.77 -14.18 -297.87 -3.62 -131.29 -257.63 179.98
Net Sales Growth(%) 0 0 0 -100 0 500 155 -100 0
EBIT Growth(%) 0 -101.99 -212.94 -47.83 86.06 -271.9 69.38 -41.37 105.26
PAT Growth(%) 0 -101.99 -226.1 -45.24 85.19 -244.22 70.17 -37.94 109.9
EPS Growth(%) 0 -101.99 0 0 85.19 -244.24 70.17 -37.94 109.9
Debt/Equity(x) 0.42 0.33 0.73 0.29 0.36 0.49 0.52 0.12 0.22
Current Ratio(x) 0.82 1.16 0.66 0.61 0.67 0.24 0.19 2.58 2.49
Quick Ratio(x) 0.82 0.53 0.32 0.16 0.33 0.21 0.17 2.52 2.44
Interest Cover(x) 0 0 -3999.18 -9181.92 -1561.4 0 -672 0 6.25
Total Debt/Mcap(x) 0 0 0 0.05 0.05 0 0.08 0 0.01

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR — — — —
Operating Profit CAGR — — — —
PAT CAGR — — — —
Share Price CAGR -58% -32% -9% —
ROE Average +2% -9% -13% -119%
ROCE Average +1% -7% -10% -24%

Transpact Enterprise Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 16.16 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 83.84 %
# Sep 2021 Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025 Mar 2026
Promoter 45.8945.8945.8932.6332.218.2316.1616.160.1316.16
FII 0000000000
DII 0000000000
Public 54.1154.1154.1167.3767.881.7783.8483.8499.8783.84
Others 0000000000
Total 100100100100100100100100100100

Transpact Enterprise Peer Comparison

Medical Equipment/Supplies/Accessories Edit Columns

Transpact Enterprise Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Transpact Enterprise Pros & Cons

Pros

  • Company is almost debt free.

Cons

  • Promoter holding is low: 16.16%.
  • Company has a low return on equity of -9% over the last 3 years.
  • Stock is trading at 8.5 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp